Analysts Set Health Catalyst, Inc. (NASDAQ:HCAT) PT at $12.10

Health Catalyst, Inc. (NASDAQ:HCAT) has earned an average recommendation of “Moderate Buy” from the eleven analysts that are covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $12.10.

A number of research firms have weighed in on HCAT. Guggenheim upgraded Health Catalyst from a “neutral” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Friday, January 26th. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research report on Wednesday, April 10th. Barclays began coverage on Health Catalyst in a research report on Wednesday, January 3rd. They set an “overweight” rating and a $14.00 price target on the stock. Evercore ISI lowered their price target on Health Catalyst from $11.00 to $10.00 and set an “outperform” rating on the stock in a research report on Friday, February 23rd. Finally, KeyCorp reiterated a “sector weight” rating on shares of Health Catalyst in a report on Wednesday, April 10th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Nepsis Inc. increased its holdings in Health Catalyst by 6.0% during the 1st quarter. Nepsis Inc. now owns 1,157,394 shares of the company’s stock valued at $8,715,000 after purchasing an additional 65,462 shares during the period. Los Angeles Capital Management LLC increased its holdings in Health Catalyst by 386.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 56,785 shares of the company’s stock valued at $428,000 after purchasing an additional 45,115 shares during the period. Goldman Sachs Group Inc. increased its holdings in Health Catalyst by 38.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,220,627 shares of the company’s stock valued at $11,303,000 after purchasing an additional 335,823 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Health Catalyst by 11.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,915 shares of the company’s stock valued at $435,000 after purchasing an additional 4,941 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in Health Catalyst during the 4th quarter valued at about $369,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst Price Performance

NASDAQ:HCAT opened at $5.70 on Friday. The firm has a market capitalization of $333.50 million, a price-to-earnings ratio of -2.71 and a beta of 1.29. Health Catalyst has a 52-week low of $5.51 and a 52-week high of $14.37. The stock has a fifty day moving average of $7.88 and a 200 day moving average of $8.44. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.42 and a current ratio of 4.42.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.06. Health Catalyst had a negative return on equity of 12.19% and a negative net margin of 39.92%. The business had revenue of $75.08 million for the quarter, compared to the consensus estimate of $73.67 million. On average, research analysts expect that Health Catalyst will post -0.47 EPS for the current fiscal year.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.